z-logo
HomeZAIABlog
open-access-imgOpen Access
Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US
Author(s) -
Tina R. Watson,
Xīn Gào,
Kerry L. Reynolds,
Chung Yin Kong
Publication year - 2020
Publication title -
jama network open
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.278
H-Index - 39
ISSN - 2574-3805
DOI - 10.1001/jamanetworkopen.2020.16144
Subject(s) - nivolumab , ipilimumab , pembrolizumab , medicine , axitinib , renal cell carcinoma , population , oncology , kidney cancer , cancer , sunitinib , immunotherapy , environmental health
This economic evaluation compares the cost-effectiveness of pembrolizumab-axitinib vs nivolumab-ipilimumab for treatment of advanced renal cell carcinoma (ARCC) in the US.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

AboutCareersPublisher PartnersContact UsGet Organisational Trial or Quote

Learn

FAQsBlogTerms of UsePrivacy Policy

Download the Zendy App

Get it on
Google Play
Download on the
App Store

Discover

Explore

Copyright Knowledge E © 2026. All Rights Reserved.